AstraZeneca cancer drug Imfinzi gets USFDA priority review
AstraZeneca said the USFDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.
New Delhi: British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.
The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.
Read Also: AstraZeneca leukemia drug Calquence gets USFDA okay
A final decision is expected in the first quarter of 2020.
Read Also: AstraZeneca CKD anaemia drug Roxadustat shows increased haemoglobin levels in Phase 3 trial
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd